Lemon administration also yielded significant improvements in AD pathophysiology, increasing LRP1 expression by 6.8-fold and reducing ApoE4, NLRP3, and CASP-1 levels by 69.6%, 48.2%, and 65.6%, respectively, compared to the AD group. This evidence concerns the gene LRP1 and Alzheimer disease.